Compare CYTK & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | HRL |
|---|---|---|
| Founded | 1997 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.6B |
| IPO Year | 2004 | 1994 |
| Metric | CYTK | HRL |
|---|---|---|
| Price | $62.30 | $20.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 23 | 10 |
| Target Price | ★ $109.40 | $25.31 |
| AVG Volume (30 Days) | 2.0M | ★ 4.2M |
| Earning Date | 11-04-2026 | 12-03-2026 |
| Dividend Yield | N/A | ★ 5.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $13,368,000.00 | ★ $12,106,160,000.00 |
| Revenue This Year | $72.63 | $0.18 |
| Revenue Next Year | $181.06 | $1.84 |
| P/E Ratio | ★ N/A | $28.01 |
| Revenue Growth | N/A | ★ 1.55 |
| 52 Week Low | $54.30 | $18.96 |
| 52 Week High | $88.31 | $26.60 |
| Indicator | CYTK | HRL |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 50.08 |
| Support Level | $59.21 | $19.56 |
| Resistance Level | $67.65 | $20.38 |
| Average True Range (ATR) | 2.01 | 0.37 |
| MACD | 0.31 | 0.17 |
| Stochastic Oscillator | 34.67 | 82.74 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (less than 6%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.